Indications and Options for Systemic Therapy in Melanoma

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 1049-1058

  Sondak, Vernon K ^a,b   Gibney, Geoffrey T ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adjuvant therapy; Immunotherapy; Melanoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; DABRAFENIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER STAGING; CUTANEOUS MELANOMA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; REVIEW; SYSTEMIC THERAPY; ADJUVANT THERAPY; ALGORITHM; CLINICAL TRIAL (TOPIC); METHODOLOGY; MULTIMODALITY CANCER THERAPY; RISK FACTOR; SKIN TUMOR; TARGETED THERAPY;

ADJUVANT THERAPY; IMMUNOTHERAPY; MELANOMA; TARGETED THERAPY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERONS; MELANOMA; MOLECULAR TARGETED THERAPY; RISK FACTORS; SKIN NEOPLASMS;

EID: 84907676513     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.007     Document Type: Review

References (52)

1. McArthur G.A., Ribas A. Targeting oncogenic drivers and the immune system in melanoma. JClin Oncol 2013, 31:499-506.
2. Kirkwood J.M., Manola J., Ibrahim J., et al. Apooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
3. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. JNatl Cancer Inst 2010, 102:493-501.
4. Mocellin S., Lens M.B., Pasquali S., et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013, (6). CD008955.
5. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. Overall results of a randomized trial of the Southwest Oncology Group. JClin Oncol 2002, 20:2058-2066.
6. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
7. Sosman J.A., Weeraratna A.T., Sondak V.K. When will melanoma vaccines be proven effective?. JClin Oncol 2004, 22:387-389.
8. Schwartzentruber D.J., Lawson D.H., Richards J.M., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. NEngl J Med 2011, 364:2119-2127.
9. Rosenberg S.A., Yang J.C., Sherry R.M., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
10. Pilon-Thomas S., Kuhn L., Ellwanger S., et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. JImmunother 2012, 35:615-620.
11. Yao S., Zhu Y., Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013, 12:130-146.
12. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
13. Phan G.Q., Weber J.S., Sondak V.K. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 2008, 15:3014-3021.
14. Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013, 19:5300-5309.
15. Topalian S.L., Sznol M., McDermott D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. JClin Oncol 2014, 32:1020-1030.
16. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEngl J Med 2013, 369:134-144.
17. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. NEngl J Med 2013, 369:122-133.
18. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366:2443-2454.
19. Weber J.S., Kudchadkar R.R., Yu B., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. JClin Oncol 2013, 31:4311-4318.
20. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 418:949-954.
21. McArthur G.A., Chapman P.B., Robert C., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
22. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
23. Gibney G.T., Messina J.L., Fedorenko I.V., et al. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013, 10:390-399.
24. Zimmer L., Hillen U., Livingstone E., et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. JClin Oncol 2012, 30:2375-2383.
25. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367:107-114.
26. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367:1694-1703.
27. Kaufman H.L., Kirkwood J.K., Hodi F.S., et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013, 10:588-598.
28. Sosman J.A., Moon J., Tuthill R.J., et al. Aphase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group clinical trial S9430. Cancer 2011, 117:4740-4746.
29. Howard J.H., Thompson J.F., Mozzillo N., et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012, 19:2547-2555.
30. Wevers K.P., Hoekstra H.J. Stage IV melanoma: completely resectable patients are scarce. Ann Surg Oncol 2013, 20:2352-2356.
31. Kudchadkar R., Gibney G., Sondak V.K. Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol Biol 2014, 1102:27-42.
32. Wilmott J.S., Tembe V., Howle J.R., et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012, 11:2704-2708.
33. Hodi F.S., Corless C.L., Giobbie-Hurder A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. JClin Oncol 2013, 31:3182-3190.
34. Kenchappa R.S., Tran N., Rao N.G., et al. Novel treatments for melanoma brain metastases. Cancer Control 2013, 20:298-306.
35. Gibney G.T., Sondak V.K. Has targeted therapy for melanoma made chemotherapy obsolete?. Lancet Oncol 2013, 14:676-677.
36. Hersh E., Del Vecchio M., Brown M., et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012, 25:863. [abstract].
37. Flaherty K.T., Lee S.J., Zhao F., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. JClin Oncol 2013, 31:373-379.
38. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. JClin Oncol 2010, 28:2452-2459.
39. Sarnaik A.A., Yu B., Yu D., et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011, 17:896-906.
40. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. NEngl J Med 2006, 355:1307-1317.
41. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JClin Oncol 1996, 14:7-17.
42. McArthur G.A. Adjuvant interferon in melanoma: is duration of therapy important?. JClin Oncol 2014, 32:171-173.
43. Hancock B.W., Wheatley K., Harris S., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. JClin Oncol 2004, 22:53-61.
44. Schuchter L.M. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?. JClin Oncol 2004, 22:7-10.
45. Grob J.J., Dreno B., de la Salmonière P., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998, 351:1905-1910.
46. Ascierto P.A., Kirkwood J.M. Adjuvant therapy of melanoma with interferon: lessons of the past decade. JTransl Med 2008, 6:62.
47. Eggermont A.M., Suciu S., Testori A., et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. JClin Oncol 2012, 30:3810-3818.
48. McMasters K.M., Edwards M.J., Ross M.I., et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010, 252:460-465.
49. Eggermont A.M., Suciu S., Testori A., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
50. Daud A.I., Xu C., Hwu W.J., et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2011, 67:657-666.
51. Coit DG, Thompson JA, Andtbacka R, etal. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 4, 2014. Available at: . Accessed July 19, 2014. http://NCCN.org.
52. Eggermont A.M., Chiarion-Sileni V., Grob J.J., et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol 2014, 32(Suppl):LBA9008.